Skip to main contentSkip to breadcrumbsSkip to sub navSkip to doormat

Johannes Zuber

The genetic complexity, heterogeneity, and plasticity of human cancers pose a daunting challenge for the development of effective targeted therapies. Despite their diversity, individual mutations converge at the functional level to dysregulate a limited number of cellular processes, which not only promote malignant growth but are thought to result in cancer-specific dependencies that can be exploited for therapeutic purposes. To systematically explore such ‘non-oncogene addictions’ and study them in a physiologically relevant setting, our lab combines genetically engineered mouse models (GEMMs) and advanced miRNA-based shRNA (shRNAmir) technologies optimized for multiplexed screening and studies in vivo.

Group Members

Ines AMORIM MONTEIRO BARBOSA
Research Associate
Aleksandra BUNDALO
Master Student
Melanie Talata DE ALMEIDA
PhD Student
Sumit DESWAL
Postdoc
Anja EBERT
Research Associate
Michaela FELLNER
Research Assistant
Matthias HINTERNDORFER
PhD Student
Julian JUDE
Postdoc
Robert Wolfgang KALIS
Jesse Jonathan LIPP
Bioinformatician
Matthias MUHAR
PhD Student
Sarah Christine RIESER
PhD Student
Markus SCHÄFER
Postdoc
Johannes SCHMÖLLERL
Monika STEININGER
PhD Student
Martina WEIßENBÖCK
Research Assistant
Johannes ZUBER
Group Leader